Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.
A year ago, Brenus was selected to participate in CDL Cancer, a global mentorship program for massively scalable, science-based and innovative companies accelerating cancer treatment.
Thanks to its pioneering STC platform, dedicated to developing a new generation of therapeutic cancer vaccines, Brenus stood out during a scientific evaluation with Dr. John Bell (Principal Senior Scientist at Ottawa Hospital Cancer Research Institute & Professor of Medicine & Immunology at University of Ottawa).
Brenus has graduated from the program along with 9 other companies, successfully completing the 4 sessions that took place from October 2023 to June 2024 across North America.
In this program, Brenus came to seek strategic, international guidance for the development of its platform and their lead candidate targeting colorectal cancer.
During each session, the objectives and updates presented were challenged by the CDL community and mentors: successful entrepreneurs, investors, corporate partners, KOLs, and more, all coming from prestigious institutions (University of New York, Oxford, Toronto, British Columbia). The support received was instrumental in validating Brenus Pharma’s roadmap and accelerating the achievement of strategic milestones in R&D (multi-omics and AI), finance and partnerships.
“The CDL sessions, based on an interesting “creative destruction” method, allowed us to leverage expertise across the CDL community and anticipate the next key steps to bring our innovation to patients with urgent unmet needs. This year has already been rich in achievements for Brenus, and we will continue to drive operational excellence to bring our company further. We are proud to have up taken the CDL challenge and we thank our mentors for their trust.” said Paul Bravetti, CEO of Brenus Pharma.
About CDL Cancer
This unique CDL-Global stream brings together global leaders and experts across the cancer care continuum to support technology innovations that improve the cancer experience globally, from prevention to diagnosis, treatment, and survivorship.
About the Creative Destruction Lab
The Creative Destruction Lab (CDL) is a program for massively scalable, science-based companies. The nine-month program employs an objectives-based mentoring process with the goal of maximizing equity-value creation. The CDL is particularly suited to early stage companies with links to university research labs. Launched in 2012 at the Rotman School of Management at the University of Toronto, the program has now expanded with locations in Vancouver, Calgary, Montreal, Halifax, and New York City.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627958275/en/
Contacts
Marion BRUN, contact@brenus-pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Post Quantum Cryptographic Algorithm Certificates Issued16.8.2024 21:36:00 EEST | Press release
NIST published the final version of FIPS 203 (ML-KEM), FIPS 204 (ML-DSA), and FIPS 205 (SLH-DSA) on August 13, 2024, making the first post-quantum cryptographic (PQC) algorithms official and wrapping up an eight-year effort to prepare us for a future where quantum cyberattacks are a more common threat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240816465334/en/ The first PQC algorithm certificates issued. (Photo: Business Wire) NIST enabled the ACVTS (Automated Cryptographic Validation Test System) for these algorithms on that same day, and atsec is pleased to announce it successfully performed the world’s first algorithm testing of ML-KEM and ML-DSA using ACVTS, obtaining the first associated CAVP certificates covering all supported algorithm options and key sizes mere hours later. atsec is excited to announce that testing of these post-quantum algorithms is available for all vendors, with services including providing t
Agendia Achieves CE-IVDR Certification for its MammaPrint ® and BluePrint ® Breast Cancer Assays16.8.2024 13:00:00 EEST | Press release
Agendia, Inc. today announced that it has obtained certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three products, including its MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray, and MammaPrint® and BluePrint® NGS Kit. These products are classified as Class C under this regulation. This certification recognizes Agendia’s strict adherence to rigorous quality and safety standards and ensures the tests’ reliability and effectiveness in clinical settings across the EU. “We are very proud to receive the IVDR certification for our MammaPrint and BluePrint tests and look forward to continuing our efforts in providing accurate and effective test results to those undergoing breast cancer treatment,” said Mark R. Straley, Chief Executive Officer of Agendia. “This achievement not only underscores our commitment to delivering the highest standard of care to patients, but also highlights our ability to meet the stringent regulatory requirem
Eccentrica Unveils Fully Drivable Vehicle Featuring a Naturally Aspirated V12 Engine at The Quail, A Motorsports Gathering16.8.2024 03:00:00 EEST | Press release
Eccentrica, a San Marino-based restomod manufacturer, globally unveiled its fully drivable Eccentrica V12, a modern interpretation of the legendary Lamborghini Diablo, at The Quail, A Motorsports Gathering. The limited-production vehicle combines the Diablo's classic aesthetics with cutting-edge technology and showcases for the first time a powerful new 60° naturally aspirated V12 engine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815233230/en/ Eccentrica V12 (Photo: Business Wire) Under the hood, the Eccentrica V12 houses a 5.7-liter V12 engine derived from the early '90s first generation Diablos, producing an impressive 550 HP and 600 Nm of torque. The engine is paired with a new custom-made 6-speed transmission, offering updated gear ratios and a new power steering system for optimal performance, a feature that was absent in the first series Diablo (1991-1994). New camshafts, electronic throttle body, and an optimiz
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® ) in Relapsed or Refractory Follicular Lymphoma15.8.2024 23:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint of progression free survival (PFS) by investigator assessment in FL. It also met key secondary endpoints of PFS in the overall population by investigator assessment as well as the positron-emission tomography-complete response rate in the FDG-avid FL population. In addition, the secondary endpoint of PFS results by blinded independent review are consistent with investigator based PFS results. No new safety signals with tafasitamab were observed. “While many patients with follicular lymphoma initially benefit from first-line treatment, relapse of the disease
ReNew Announces Results for the First Quarter for Fiscal Year 2025 (Q1 FY25), ended June 30, 2024 24% surge in operating capacity YoY; reiterates FY25 MW and EBITDA guidance15.8.2024 23:30:00 EEST | Press release
ReNew Energy Global Plc (“ReNew” or “the Company”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for the three-month period ended June 30, 2024. Operating Highlights: As of June 30, 2024, the Company’s portfolio consisted of ~15.6 GWs, of which ~9.6 GWs are commissioned and ~6.0 GWs are committed, compared to ~13.7 GWs as of June 30, 2023. The Company’s commissioned capacity has increased 14.0% year-over-year to ~9.6 GWs as of June 30, 2024. Subsequent to the end of the quarter, the Company commissioned 400 MWs of solar and 14 MWs of wind capacity, taking the total commissioned capacity to ~10 GWs as of August 15, 2024. Revenue for Q1 FY25 was INR 22,811 million (US$ 274 million), compared to INR 21,250 million (US$ 255 million) for Q1 FY24. Net profit for Q1 FY25 was INR 394 million (US$ 5 million) compared to INR 2,983 million (US$ 36 million) for Q1 FY24. Adjusted EBITDA for Q1 FY25 was INR 18,979 million (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom